An improved understanding of the anti-tumor CD8 + T cell response after checkpoint blockade would enable more informed and effective therapeutic strategies. Here we examined the dynamics of the effector response of CD8 + tumor-infiltrating lymphocytes (TILs) after checkpoint blockade therapy. Bulk and single-cell RNA profiles of CD8 + TILs after combined Tim-3+PD-1 blockade in preclinical models revealed significant changes in the transcriptional profile of PD-1 À TILs. These cells could be divided into subsets bearing characterstics of naive-, effector-, and memory-precursor-like cells. Effectorand memory-precursor-like TILs contained tumorantigen-specific cells, exhibited proliferative and effector capacity, and expanded in response to different checkpoint blockade therapies across different tumor models. The memory-precursor-like subset shared features with CD8 + T cells associated with response to checkpoint blockade in patients and was compromised in the absence of Tcf7. Expression of Tcf7/Tcf1 was requisite for the efficacy of diverse immunotherapies, highlighting the importance of this transcriptional regulator in the development of effective CD8 + T cell responses upon immunotherapy.
INTRODUCTION
The CD8 + T cell response within the tumor microenvironment (TME) is transcriptionally (Singer et al., 2016; Tirosh et al., 2016; Zheng et al., 2017) and functionally (Sakuishi et al., 2010; Woo et al., 2012; Xu et al., 2015) heterogeneous. At one end of the spectrum are CD8 + tumor-infiltrating lymphocytes (TILs) that lack the expression of co-inhibitory or immune checkpoint receptors (e.g., CTLA-4 and PD-1) and exhibit effector potential, while at the opposite end are CD8 + TILs that co-express multiple checkpoint receptors and exhibit an ''exhausted'' or dysfunctional phenotype. Checkpoint blockade immunotherapy, using antibodies against checkpoint receptors, is associated with improved CD8 + T cell responses in multiple pre-clinical cancer models (Duraiswamy et al., 2013; Rangachari et al., 2012; Woo et al., 2012) and in patients (Das et al., 2015; Gubin et al., 2014; Huang et al., 2017; Kamphorst et al., 2017; Yuan et al., 2008) . Accordingly, the success of checkpoint receptor blocking antibodies is attributed to the direct blockade of these receptors on dysfunctional CD8 + T cells, thereby reinvigorating their effector functions. However, it remains unclear whether checkpoint blockade therapy can also act on other cells in the TME to generate an environment that promotes optimal differentiation of T cell precursors into functional effector cells. Recent studies suggest that PD-1 blockade acts on a distinct subset of PD-1 + precursors that reside in lymphoid organs in the setting of chronic viral infection (Im et al., 2016; Utzschneider et al., 2016) and that a similar population may exist in tumor tissue (Brummelman et al., 2018) . However, PD-1 + CD8 + T cells have limited potential to give rise to a long-lasting effector response due to their acquisition of a stable epigenetic state that cannot be reverted by therapy (Ghoneim et al., 2017; Pauken et al., 2016; Philip et al., 2017; Scott-Browne et al., 2016; Sen et al., 2016) . These observations raise the important question of which cells give rise to the effector T cells that expand after checkpoint blockade therapy and are responsible for the therapeutic effect. Understanding which CD8 + TILs give rise to the effector response upon checkpoint blockade could enable not only improved strategies for harnessing the CD8 + T cell response to fight cancer, but also the identification of biomarkers to track responses to therapy.
To address this question, we examined changes in the RNA profiles of population and single CD8 + TILs after Tim-3+PD-1 blockade in a preclinical model of colon cancer. The most significant transcriptional change in CD8 + TILs after checkpoint blockade occurred in cells that lack expression of PD-1 and other checkpoint receptors. In-depth analyses of PD-1 À CD8 + TILs revealed three subsets that share features with naive, memory-precursor, and effector CD8 + T cells and change in their proportion in response to different checkpoint blockade therapies across different cancers. The number of memoryprecursor-like CD8 + T cells increased upon therapy and shared features with human CD8 + T cells that are associated with favorable prognosis and response to checkpoint blockade in cancer patients. The transcription factor Tcf7/Tcf1 was a critical regulator of this subset, and we found that checkpoint blockade and innate agonist immunotherapies failed in its absence. Thus, examination of the dynamics of the development of the effector CD8 + T cell response in the TME in the context of immunotherapy suggests a central role for PD-1 À CD8 + TILs and argues for the importance of further defining the mechanisms underlying the response to checkpoint blockade therapies.
RESULTS

Checkpoint Blockade Results in Profound Transcriptional Changes in CD8 + TILs that Lack Coinhibitory Receptor Expression
We have previously demonstrated that Tim-3 and PD-1 can be used to identify CD8 + TILs at opposite ends of the functional spectrum: Tim-3 + PD-1 + CD8 + TILs are severely dysfunctional, whereas Tim-3 À PD-1 À CD8 + TILs exhibit effector potential (Fourcade et al., 2010; Sakuishi et al., 2010) , with each population harboring distinct transcriptional profiles (Singer et al., 2016) . To determine the functional and transcriptional heterogeneity within CD8 + TILs, we generated a dysfunction signature defined as the differentially expressed genes between Tim-3 À PD-1 À and
Tim-3 + PD-1 + CD8 + TILs (STAR Methods) and scored this signature in our previously reported scRNA-seq profile of CD8 + TILs from B16F10 melanoma (Singer et al., 2016) . We observed a gradient of low to high expression of the dysfunction signature across single CD8 + TILs ( Figure 1A ). As expected, cells with low expression of the dysfunction signature were negative for checkpoint receptors, such as Tim-3, PD-1, Lag-3, and TIGIT ( Figure 1B ).
We next determined the effect of checkpoint blockade therapy on Tim-3 À PD-1 À and Tim-3 + PD-1 + CD8 + TIL populations, considering that checkpoint receptor blockade could impact these populations either directly or indirectly due to the expression of checkpoint receptors on multiple immune cell populations in the TME (da Silva et al., 2014; Gordon et al., 2017; Jiang et al., 2016; Krempski et al., 2011; Lim et al., 2015; Sakuishi et al., 2013) . We used ovalbumin-expressing MC38 colon carcinoma (MC38-OVA) to enable tracking of endogenous T cell responses to the tumor-expressed OVA antigen. We treated MC38-OVA tumor-bearing mice with a combination of anti-Tim-3 and anti-PD-1 antibodies (hereafter referred to as Tim-3+PD-1 blockade) ( Figure 1C ), given the demonstrated efficacy of this antibody combination in multiple tumor models (Ngiow et al., 2011 (Table S1 ).
However, analysis of multiple effector CD8 + T cell signatures (Hervas-Stubbs et al., 2010; Kaech et al., 2002; Kalia et al., 2010; Sarkar et al., 2008) Figure 1E ). We identified 39 genes that were increased in both subsets (Table S2) . These included effector genes such as Ifng, Tnfa, and Gzmb and transcription factors such as Tbx21; however, these and other well-known effector genes showed greater treatmentinduced changes in Tim-3 À PD-1 À as compared to Tim-3 + PD-1 + CD8 + TILs ( Figure 1F ). Thus, checkpoint blockadeinduced transcriptional changes were consistent with acquisition of effector potential in CD8 + TILs, and this occurred to a significantly greater extent in CD8 + TILs that lack expression of co-inhibitory receptors. (Ahn et al., 2016; Ghoneim et al., 2017; Pauken et al., 2016; Sen et al., 2016; Utzschneider et al., 2013) , we focused on understanding the changes within PD-1 À
CD8
+ TILs (cells that are PD-1 À are uniformly negative for Tim-3 and other checkpoint receptors) and their relationship to PD-1 + CD8 + TILs. We quantified the numbers of PD-1 À and PD-1 + CD8 + TILs after each anti-Tim-3+anti-PD-1 treatment and found increased numbers of PD-1 À but not PD-1 + CD8 + TILs after three treatments ( Figure 2A ). This was due to increased proliferation of PD-1 À CD8 + TILs as determined by Ki67 expression ( Figure 2B ). (Singer et al., 2016) .
(C-F) C57BL/6 mice were implanted subcutaneously with MC38-OVA and treated with either rat IgG2a (blue) or anti-Tim-3 (RMT3-23) and anti-PD-1 (RMP1-14) (red) on days 4, 7, and 10. (E) Wheel graphs showing enrichment of effector signatures (Hervas-Stubbs et al., 2010; Kaech et al., 2002; Kalia et al., 2010; Sarkar et al., 2008) and PD-1 + CD8 + TILs from MC38-OVA tumor-bearing mice and adoptively transferred the two subsets into RAG À/À mice that were subsequently implanted with MC38-OVA ( Figure 2D ). In line with observations in chronic viral infection models, we found that PD-1 expression remained stable on transferred PD-1 + cells (Ahn et al., 2016; Utzschneider et al., 2013 
+ TILs within our previously reported scRNA-seq profile from untreated mice (Singer et al., 2016) . This highlighted two distinct sets of cells within PD-1 À CD8 + TILs ( Figure 3A ). Group 1 cells expressed genes that were increased after Tim-3+PD-1 blockade, whereas group 2 cells expressed genes that were higher in the isotypetreated group. This suggested that both groups of cells exist even in the absence of checkpoint blockade and that the differences observed in bulk RNA profiles reflected proportional changes in pre-existing sub-populations. Moreover, group 1 cells also showed higher expression of a CD8 + T cell effector signature (Kaech et al., 2002) than group 2 cells ( Figure 3B) Figure 3C ). Together, these data indicate that there are distinct subsets within PD-1 À CD8 + TILs that differ in their expression of effector (group 1) and naive/memory (group 2) programs.
PD-1 -CD8 + TIL Subsets Exhibit Properties of Naive, Effector, and Memory-Precursor T Cells To better characterize the cells in group 1 and group 2, we sought to identify surface markers that could distinguish them. We identified CX3CR1 and KLRG1 for group 1 and CD62L for group 2 based on their differential expression (Figure 3C) and their known associations with effector and naive CD8 + T cell subsets (Bö ttcher et al., 2015; Gerlach et al., 2016; Joshi et al., 2007; Lefranç ois, 2006) . We additionally used Slamf7 for group 1. Consistent with their differential expression in group 1 and 2 cells, CD62L expression marked a subset of PD-1 À CD8 + TILs distinct from those expressing CX3CR1 and KLRG1 ( Figure S1A Figure 4F and Table S3 ), with the CD62L À Slamf7 hi CX3CR1 À subset sharing some transcriptional 5C ). In line with our previous data ( Figure 4E ), we did not observe OVA-specific CD8 + TILs within the naive-like subset ( Figure 5C ).
Together, these data indicated that tumor antigen-specific CD8 + T cells within the memory-precursor and effector-like PD-1 À
+ TILs expanded upon checkpoint blockade.
We next addressed whether similar shifts within PD-1 À CD8 + TILs were detected in response to different therapies and in different tumor types. We examined CTLA-4+PD-L1 blockade Figure S2 .
in MC38-OVA and observed increases in the memory-precursor-and effector-like subsets ( Figure 5D ). We further confirmed these findings in B16F10 melanomabearing mice treated with CTLA-4+PD-1 blockade ( Figure 5E ) and Tim-3+PD-1 blockade ( Figure S2B ). These data indicate that our observations are generalizable to other checkpoint blockade therapies and other cancer types and show that the changes in PD-1 À
+ TILs are not due to antibody-induced PD-1 down-modulation on the surface of CD8 + TILs.
Checkpoint Blockade-Induced Memory and Effectorlike Transcriptional Programs in Murine and Human Cancer
To determine whether changes in the naive-, memory-precursor-, and effector-like PD-1 À TIL subsets captured all of the changes occurring within PD-1 À CD8 + TILs after checkpoint blockade, we performed scRNA-seq of PD-1 À
CD8
+ TILs from MC38-OVA tumor-bearing mice treated with Tim-3+PD-1 blockade or isotype control. We found a major shift in the proportion of cells in different transcriptional clusters ( Figure 6A , panel I). Unsupervised clustering of the cells' profiles showed that all clusters had representation from both treated and control mice, but at dramatically different proportions (Figures 6A, panels I and II, 6B, and S3A). Clusters 1, 5, 7, and 8 were enriched for cells from isotype-treated mice while clusters 3, 4, and 6 were enriched for cells from Tim-3+PD-1 blockade-treated mice. Indeed, clusters 3, 4, and 6 were also enriched for cells expressing an effector CD8 + T cell signature (Kaech et al., 2002) ( Figure Figure S3C ), indicating that Tim-3+PD-1 blockade elicited a pro-inflammatory TME that expanded effector PD-1 À CD8 + TILs. Clustering further highlighted subtler distinctions, including naive-like cells that began to adopt features of effector cells and highly proliferative cells that retained features of memory. Specifically, the naive-like signature was expressed in cells from clusters 1, 5, 8, 7, and 9 ( Figures 6D and S3D ), but only cells in cluster 9, which had equal proportions of isotype-and Tim-3+PD-1 blockade-treated cells ( Figures 6B and S3A ), also expressed several effector genes including Gzma, Gzmb, and Ifng ( Figure 6D ). Cluster 10 cells exhibited high expression of the memory-precursor-like signature and was equally comprised of cells from both treatment groups (Figures 6A, panel V, 6B, and S3A), but a larger proportion of cells from the Tim-3+PD-1 blockade group expressed Mki67, as well as a proliferation signature (Tirosh et al., 2016) (Figure 6C ). The cells in cluster 10 also expressed Tcf7, Lef1, Ccr7, and Sell together with several effector T cell genes ( Figure 6D ). Thus, Tim-3+ PD-1 blockade induced cells within cluster 10 that are highly proliferative, exhibited features of effector cells, and retained features of naive/memory cells.
We next addressed whether the memory-precursor-and effector-like subsets that expand after therapy have relevance in human cancer. We found that TIL hi and CD103 hi Trm cell signatures that have been associated with better prognosis in NSCLC patients (Ganesan et al., 2017) were enriched for the memory-precursor-like signature relative to the effector-like signature ( Figure S4A ). Additional signatures correlated with TIL persistence and durable responses (Haymaker et al., 2015; Li et al., 2010) were also enriched for the memory-precursorlike signature ( Figure S4A ). In accordance with these findings, scoring of our PD-1 À CD8 + TIL scRNA-seq profiles also showed that the memory-precursor-and effector-like clusters (3, 4, 6, and 10) were enriched for the TIL hi versus TIL lo signature (Figures 6E and S4B; Ganesan et al., 2017) . In particular, the memoryprecursor-like cluster 10 was enriched for a signature of CD8 + T cells from either anti-PD-1 (nivolumab)-, anti-CTLA-4 (ipilimumab)-, or anti-CTLA-4+anti-PD-1-treated cancer patients (Figure 6E and S4B; Das et al., 2015) . Conversely, a signature of genes differentially expressed between naive versus antigenexperienced CD8 + T cells obtained from the peripheral blood of melanoma patients (Baitsch et al., 2011) was enriched in the naive-like clusters (1, 5, 7, 8, and 9 Figure 7A ). Tcf7, which encodes Tcf1/TCF1, was of key interest given its role in self-renewal and maintenance of memory CD8 + T cells (Jeannet et al., 2010; Zhou et al., 2010) and recent studies showing its requirement for the expansion of PD-1 + CD8 + T cells after PD-L1 blockade (Im et al., 2016; Utzschneider et al., 2016) . Tcf1 was indeed more highly expressed in the memory-precursor-like subset compared to the effector-like subset of PD-1 À CD8 + TILs ( Figure S5A ). Moreover, Tcf1 transcriptional targets, either selected from Tcf1 chromatin-immunoprecipitation sequencing (ChIP-seq) data on naive CD8 + T cells (Steinke et al., 2014) or from RNA profiling of WT versus Tcf7-deficient TCR-transgenic memory CD8 + T cells (Zhou et al., 2010) , were enriched in genes differentially expressed between the memory and effector-like subsets ( Figures 7B and 7C) .
To determine the role of Tcf1 selectively in CD8 + TILs, we generated mice that harbored deletion of Tcf7 in mature CD8 + T cells by crossing Tcf7 flox/flox mice with mice that expressed
Cre recombinase under the E8I promoter (Maekawa et al., 2008) . We did not observe any gross defects in T cell development or in the peripheral T cell compartment in these mice (Figure S5B) . We implanted MC38-OVA and did not observe significant changes in the distribution of Tim-3 + PD-1 + and Tim-3
fl/fl mice (data not shown); however, we found a significant decrease in the memory-precursor-like subset within PD-1 À CD8 + TILs in E8i-Cre + Tcf7 fl/fl mice ( Figure 7D ). This indicated an essential role for Tcf1 in the development and/or maintenance of the memory-precursor-like subset. We further observed that the frequency of OVA-specific T cells was decreased within the memory-precursor-like subset, shifting the balance toward the effector-like subset of PD-1 À CD8 + TILs ( Figure 7E ).
Overall, the frequency of OVA-specific CD8 + TILs was significantly decreased within both PD-1 À and PD-1 + CD8 + TILs in E8i-Cre + Tcf7 fl/fl mice ( Figure S6A ), suggesting that the defects in the memory-precursor-like subset were propagated to PD-1 + CD8 + TILs. Lastly, the poly-functionality of the memory-precursor-like subset in response to tumor antigen stimulation was reduced in the absence of Tcf1 ( Figure 7F ). Together these (legend continued on next page) data indicated that both the maintenance and functionality of tumor antigen-specific memory-precursor-like PD-1 À cells was impaired in the absence of Tcf1 and that the defects in these cells extended to the bulk CD8 + T cell pool. Our results indicated that the memory-precursor-like PD-1 À
+ TIL subset expanded upon Tim-3+PD-1 blockade, potentially providing a wave of effector CD8 + T cells able to sustain an effective anti-tumor response. Given that Tcf1 regulates the maintenance of this subset, we hypothesized that Tcf1 may be essential for effective immunotherapy. To test this, we treated MC38-OVA tumor-bearing WT and E8i-Cre + Tcf7 fl/fl mice with anti Tim-3+PD-1 or isotype control antibodies. Supporting our hypothesis, the efficacy of Tim-3+PD-1 blockade was lost in E8i-Cre + Tcf7 fl/fl mice ( Figure 7G ). Of note, isotype-treated E8i-Cre 
+ TIL subsets after checkpoint blockade (Figure S3C) , we next examined whether Tcf1 was required for the efficacy of a Toll-like receptor 9 (TLR9) agonist (IMO-2125, currently in clinical development) that induces pro-inflammatory cytokines (IL-12, type 1 IFN, and IL-6) (Makowska et al., 2013) in the TME and resulted in complete regression of MC38-OVA tumors in WT mice ( Figures S6B and S6C) . We treated MC38-OVA tumor-bearing WT and E8i-Cre 
DISCUSSION
We used an integrated experimental and computational approach to show that checkpoint blockade therapy recruited cells that lack expression of PD-1 and other checkpoint receptors. We identified three subsets of PD-1 À CD8 + TILs that had features of naive, memory-precursor, or effector CD8 + T cells and showed that different checkpoint blockade therapies across different cancers induced expansion of the memory-precursorand effector-like PD-1 À CD8 + TIL subsets with concomitant decrease in the naive-like subset. We further showed that the memory-precursor-like subset was compromised in the absence of Tcf7 and shared features with CD8 + T cells that correlate with better prognosis and with response to checkpoint blockade in cancer patients, highlighting the clinical relevance of our findings.
The discovery of PD-1 À CD8 + T cell subsets that change in response to immunotherapy is important in light of the recent studies describing a population of PD-1 + CD8 + T cells that expresses CXCR5 and provides the proliferative burst after PD-1 blockade during chronic viral infection (Im et al., 2016 (Ghoneim et al., 2017; Pauken et al., 2016; Philip et al., 2017; Scott-Browne et al., 2016) . Conversely, the memory-precursor-like PD-1 À CD8 + TIL subset likely contains earlier precursors that have a better capacity to persist and continuously seed the effector T cell pool to sustain longterm responses. The presence of sufficient numbers of such CD8 + TILs can be advantageous in the setting of cancer and chronic viral infection where checkpoint blockade therapy takes the brakes off chronically stimulated T cells, thereby accelerating the T cell activation and differentiation trajectory toward activation-induced cell death. Our data showed that in the absence of Tcf7/Tcf1, the memory-precursor-like subset was compromised and different immunotherapies failed. These results underscore the importance of maintaining such a TIL subset and of understanding the mechanisms underlying its regulation by Tcf7. Future adoptive transfer experiments will be required to directly demonstrate the potential of this subset to sustain effective and durable anti-tumor responses upon immunotherapy. Nonetheless, the recent demonstration that PD-1 À CAR-T cells having features of memory-like cells are predictive of complete remission in cancer patients and that an analogous population is required for tumor control in mice (Fraietta et al., 2018) supports the relevance of PD-1 À cells with memory-like features. In addition to changes in PD-1 + CD8 + TILs, our data show that checkpoint blockade therapy also induces changes in PD-1 À
CD8
+ TILs, which can contribute to the therapeutic effect. This could occur through a direct therapy-mediated effect on CD4 + regulatory T (Treg) cells, as CTLA-4 is constitutively expressed on Treg cells and Tim-3 is highly expressed on tumor-infiltrating Treg cells (Sakuishi et al., 2013) . Checkpoint blockade can also act on cells of the innate immune system. Tim-3 blockade can improve the function of natural killer cells from melanoma patients (da Silva et al., 2014) . Anti-Tim-3 and anti-PD-1 or PD-L1 antibodies can affect the phenotype of myeloid cells in the TME, abrogating the acquisition of an M2-like phenotype in tumor-associated macrophages (TAMs) (Jiang et al., 2016) and inducing type 1 IFN, IL-12, and IFN-g in CD103 + dendritic cells (DCs) in breast cancer (de Mingo Pulido et al., 2018) . Similarly, PD-1 or PD-L1 blockade can promote the release of pro-inflammatory cytokines by DCs in ovarian cancer (Krempski et al., (G) 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice 6-8 week old C57BL/6 and Rag À/À mice were purchased from the Jackson Laboratories. Embryonic stem cells with a targeted Tcf7 gene were obtained from Eucomm. Embryonic stem cells were injected into blastocysts to obtain chimeras. Presence of the targeted Tcf7 locus was confirmed by Southern Blot. Chimeras were bred to mice that transgenically express flpO recombinase (MMRC, UC Davis) to remove the neomycin cassette and then bred with mice that express Cre recombinase under the CD8 Enhancer I (E8I-Cre) that was previously described (Maekawa et al., 2008) . E8I is activated after the single positive CD8 + T cell stage in the thymus Tumor experiments MC38-OVA cell line was derived from MC38 as previously described (Gilfillan et al., 2008) . MC38-OVA (0.5x10 6 ) cells were implanted subcutaneously into the right flank. Tumor size was measured in two dimensions by caliper and is expressed as the product of two perpendicular diameters. In some experiments, mice were treated with 200 mg of anti-Tim-3 (RMT3-23) and 100 mg of anti-PD-1 (RMP1-14) antibodies or 200 mg of control immunoglobulin (Rat IgG2a) i.p. on days 4, 7 and 10 post tumor implant. Mice were either monitored for tumor growth or sacrificed on day 12 for functional and transcriptional analysis. The B16F10 cell line was purchased from ATCC. B16F10 (0. In some experiments, mice were treated with either PBS or 2 mg/kg of a TLR9 agonist (IMO-2125 provided by Sudhir Agrawal of Idera Pharmaceuticals under MTA) by intratumoral injection on days 4, 7, 10, and 13 post tumor implant. % Tumor burden change is calculated as % change in tumor size compared to the peak tumor size (day 8-10). For response to treatment, a threshold of R 30% decrease in reference to baseline is considered (Nishino et al., 2016) . For adoptive cell transfer experiments, PD1 + or PD1 -TILs were sorted from Tim-3+PD-1-treated C57BL/6 mice bearing MC38-OVA tumors at 12 days upon tumor injection. A total of 10 5 sorted cells were transferred intravenously into RAG KO donor mice that were injected subcutaneously with MC38-OVA tumors the same day.
METHOD DETAILS
Isolation of Tumor Infiltrating Lymphocytes (TILs) TILs were isolated by dissociating tumor tissue in the presence of collagenase D (2.5 mg/mL) for 20 min prior to centrifugation on a discontinuous Percoll gradient (GE Healthcare). Isolated cells were then used in various assays of T cell function (below).
Flow cytometry
Single cell suspensions were stained with antibodies against TCRb (H57-597), CD8 (53-6.7), PD-1 (RMP1-30), Tim-3 (5D12), CX3CR1 (SA011F11), CD319 (4G2), KLRG1 (MAFA) and CD62L . Fixable viability dye eF506 (ebioscience) or Zombie UV fixable viability dye (Biolegend) was used to exclude dead cells. All data were collected on a BD Fortessa (BD Biosciences) and analyzed with FlowJo software (Tree Star). To assess OVA-specific CD8 + cells, TILs were stained with H-2Kb-OVA 257-264 dextramers (Immudex) and then stained with surface antibodies. To determine Tcf1 protein levels, TILs were stained with surface antibodies then fixed and permeabilized with eBioscience Transcription Factor Staining Buffer Set. Cells were then stained with anti-Tcf1 antibody (C63D9) followed by fluorescently tagged anti-Rabbit IgG (Cell Signaling). For intra-cytoplasmic cytokine staining, cells were stimulated in vitro with 5 mg/mL OVA 257-264 peptide for 3.5 hr in the presence of Golgi stop (BD Biosciences). Cells were then harvested and stained with antibodies against surface proteins prior to fixation and permeabilization. Permeabilized cells were then stained with antibodies against IL-2 (JES6-5H4), TNF-a (MP6-XT22) and IFN-g (XMG1.2). For Granzyme B staining, TILs were stained with antibodies against surface proteins prior to fixation and permeabilization. Permeabilized cells were then stained with antibody against Granzyme B (2C5/F5). For CD107a staining, TILs were stimulated in vitro with 5 mg/mL OVA 257-264 peptide for 3.5 hr in the presence of Golgi stop and an antibody against CD107a (1D4B). Cells were then harvested and stained with antibodies against surface proteins. To assess cell proliferation, TILs were stained with surface antibodies and fixed/permeabilized with eBioscience Transcription Factor Staining Buffer Set and stained with the antibody against Ki67 (SolA15). (QIAGEN) . In all cases, full-length RNA-seq libraries were prepared as previously described (Picelli et al., 2013) using the SMART-seq2 protocol with reduced PCR cycle number (12-15 cycles) and one-fourth of the standard Illumina Nextera XT reaction volume, followed by paired-end Illumina sequencing (38bp x 2) with a 75 cycle Nextseq 500 high output V2 kit.
Population RNA-Seq data pre-processing RNA-seq reads were aligned using Tophat ) (to mouse genome version mm9), and expression levels were calculated using RSEM (Li and Dewey, 2011) using known transcripts (mm9), followed by further processing using the Bioconductor package DESeq in R (Anders and Huber, 2010) . The data was normalized using TMM normalization, and differentially expressed genes were defined using the differential expression pipeline on the raw counts with a single call to the function DESeq (FDR-adjusted P value < 0.05). Heatmap figures were generated using pheatmap package (Kolde and Vilo, 2015 Plate-based CD8 + TILs single-cell RNA-Seq CD8 + TILs data was obtained from (Singer et al., 2016) , where it was collected in 96 well plates.
Plate-based single-cell RNA-seq data processing Initial preprocessing was performed as described in (Singer et al., 2016) . Briefly, paired reads were mapped to mouse annotation mm10 using Bowtie (Langmead et al., 2009 ) (allowing a maximum of one mismatch in seed alignment, and suppressing reads that had more than 10 valid alignments) and TPMs were computed using RSEM (Li and Dewey, 2011) , and log 2 (TPM+1) values were used for subsequent analyses. Next, we filtered out low quality cells and cell doublets, maintaining for subsequent analysis the 588 cells that had (1) 1,000-4,000 detected genes (defined by at least one mapped read), (2) at least 200,000 reads mapped to the transcriptome, and (3) at least 50% of the reads mapped to the transcriptome. Here, we restricted the genes considered in subsequent analyses to be the 7,790 genes expressed at log 2 (TPM+1) R 2 in at least ten percent of the cells. After removal of low quality cells/genes, the data were normalized using quantile normalization followed by PCA. PCs 1-8 were chosen for subsequent analysis due to a drop in the proportion of variance explained following PC8. We used tSNE (Maaten, 2008) to visualize single cells in a two-dimensional non-linear embedding.
Gene signatures
Mouse CD8 + TILs dysfunction signature ( Figure 1A and 4I) was generated by using the differentially expressed genes between Tim-3 (Figure 1 and 3) was generated by using the differentially expressed genes between CD8 + TILs from MC38-OVA bearing mice treated with anti-PD1+anti-Tim-3 and isotype control (FDR-adjusted P value < 0.2, 608 and 364 DE genes respectively). CD8 + T cell effector signatures ( Figure 1 ) were downloaded from MSigDB: Day 4.5 effector CD8 + T cell and KLRG1 hi CD8 + T cell signatures (Sarkar et al., 2008) , Day 3 effector CD8 + T cell (Kalia et al., 2010) , for day 8 effector CD8 + T cell, (Kaech et al., 2002) , and for in vitro activated CD8 + T cells (Hervas-Stubbs et al., 2010) .
Cytokine signatures ( Figure S3 ): IFN-g and IFN-b signatures were from (Iwata et al., 2017)- + T cells after 6h, 24h and 72h with or without cytokine treatment. IL-6 signature was defined by differentially expressed genes between cytokine treated and non-treated naive CD4 + T cells for 72h using RNaseq data from (Hirahara et al., 2015) (FDRadjusted P value < 0.05, 116 DE genes; bioconductor package DESeq2 (Love et al., 2014) ). IL-12 signature was defined by differentially expressed genes between CD8 + T cells stimulated with or without IL-12 for 48h using microarray data from (Agarwal et al., 2009 ) (P value < 0.05 and log 2 (fold change) > 0.7, 527 DE genes, Limma package).
Gene sets for naive cells ( Figure 4G ) were downloaded from MSigDB (Kaech et al., 2002) . Microarray dataset of memory-precursor and effector CD8 + T cell data was downloaded from (Joshi et al., 2007) (Figure 4H ). Limma package was used to estimate the fold changes and standard errors by fitting a linear model for each gene for the assessment of differential expression (p.value < 0.05 and log 2 (fold change) > 2, 2,036 DE genes). CD8 + T cells signatures were downloaded from MSigDB. For KLRG1 hi versus KLRG1 int and memory versus day 4.5 effector (Sarkar et al., 2008) , day 8 and day 15 effector versus memory CD8 + T cells is from (Kaech et al., 2002) and another effector versus memory CD8 + T cell signature is from (Luckey et al., 2006) (Figure 4I ). Tcf7 ChIP-Seq data ( Figure 7B ) for naive CD8 + T cells was downloaded from (Steinke et al., 2014) . ChIPpeakAnno R package (Zhu et al., 2010 ) was used to annotate CHIP-Seq peaks to gene promoter regions based on the following thresholds (upstream = 1000, downstream = 500 of TSS). Microarray gene expression data from Tcf7 À/À memory CD8 + T cells ( Figure 7C ) was downloaded from (Zhou et al., 2010) . Limma package was used for the assessment of differential expression (p value < 0.05 and log 2 (fold-change > 0.7), 253 DE genes). Human Gene sets used for TIL hi versus TIL lo and CD103 hi and CD103 lo ( Figure S4A and Figure 6E ) signatures are from n = 36 NSCLC patients (Ganesan et al., 2017) (Tables S6 and S7 ). CD28 + versus CD28 -CD8 + TILs microarray data are from n = 3 expanded TIL lines (Li et al., 2010) and BTLA + versus BTLA -CD8 + TILs microarray data are from n = 5 melanoma patients (Haymaker et al., 2015) ( Figure S4A ).
Limma package was used for the assessment of differential expression (p value < 0.05 and log 2 (fold change) > 0.7, 1146 and 124 DE genes respectively). Proliferation signature is taken from (Tirosh et al., 2016) (Figure 6C ). Gene sets for naive (n = 13) versus antigenspecific CD8 + T cells (n = 19) are from (Baitsch et al., 2011) . Microarray data of blood CD8 + T cells after anti-CTLA-4 (n = 5), anti-PD-1 (n = 6), or anti-PD-1+anti-CTLA-4 (n = 6) treatment was downloaded from (Das et al., 2015) ( Figure 6E and S4B). Limma package was used for the assessment of differential expression (p value < 0.05, 548, 244 and 800 DE genes respectively).
Single-cell gene signature scoring As an initial step, the data was scaled (z-score across each gene) to remove bias toward highly expressed genes. Given a gene signature (list of genes), a cell-specific signature score was computed by first sorting the normalized scaled gene expression values for each cell followed by summing up the indices (ranks) of the signature genes. For gene-signatures consisting of an upregulated and downregulated set of genes, two ranking scores were obtained separately, and the downregulated associated signature score was subtracted from the upregulated generated signature score. A contour plot was added on top of the tSNE space, which takes into account only those cells that have a signature score above the indicated threshold to further emphasis the region of highly scored cells.
As background to assess significance, we used a scheme that controls for expression of the signature using expression-levelmatched subsets of genes. The p value for each cell is calculated by generating random sets of signatures that are composed of genes with a similar average and variance expression levels as the original signature. This was followed by comparing the generated scores to the score obtained from the original signature. Cells that had a statistically significant score (FDR-adjusted P value < 0.05) were marked by '+' ( Figure S4B ). Statistical significance for the human signatures for each of the clusters in Figure 6E was calculated by averaging the human signature scores across the cells that compose each cluster and comparing them to random sets of signatures as described above. Clusters that had a statistically significant score (FDR-adjusted P value < 0.05) were marked by '+' ( Figure S4B ).
Droplet-based single-cell RNA-Seq of Tim-3 -PD-1 -CD8 + TILs Tim-3 -PD-1 -CD8 + TILs were sorted from MC38-OVA tumor-bearing mice that were treated with anti-PD-1 and anti-Tim-3 antibodies or isotype controls and were encapsulated into droplets, and libraries were prepared using Chromium Single Cell 3 0 Reagent Kits v2 according to manufacturer's protocol (10 3 Genomics). The generated single cell RNA-seq libraries were sequenced using a 75 cycle Nextseq 500 high output V2 kit.
Droplet-based single-cell RNA-Seq data processing Gene counts were obtained by aligning reads to the mm10 genome using CellRanger software (v1.3 10 3 Genomics). To remove doublets and poor-quality cells, we removed cells that contained more than 10% mitochondrially derived transcripts, or where less than 500 genes were detected. Among the retained cells, we considered only genes that are present in > 30 cells and have > 60 transcripts summed across all the selected cells, yielding 5,457 cells and 9,505 genes. Transcript count for each library was normalized to the median of the transcript counts across all cells. For PCA and clustering, we used a log-transformed expression matrix. The top 13 PCs were included for subsequent tSNE analysis, determined by a drop in the proportion of variance explained by subsequent PCs. We confirmed that the resulting analyses were not particularly sensitive to this choice.
Single cell RNA-seq clustering Cells were clustered based on their top 13 PCs scores using the Louvain-Jaccard graph clustering algorithm (Blondel et al., 2008) as previously described (Levine et al., 2015; Shekhar et al., 2016) . Shifts in the distribution of Tim-3 -PD-1 -CD8 + TILs from mice treated with anti-PD-1 and anti-Tim-3 antibodies or isotype controls for each of the clusters were calculated using Fisher's exact test.
Differentially expressed genes between clusters
We used a binomial test to find genes differentially expressed (DE) between clusters, as previously described (Shekhar et al., 2016) . To find marker genes for subpopulation A against all the other cell types in the data, we pooled the cells from all the subpopulations except A, and regarded this pool as subpopulation B. We corrected for multiple hypothesis testing with a Benjamini-Hochberg FDR. A gene was considered statistically significant if it satisfied FDR < 0.01.
Visualization of single cell data
To generate tSNE plots (Maaten, 2008) of single cell profiles, the scores along the 13 significant PCs estimated above were used as input to the R implementation of tSNE (Maaten, 2009; Maaten, 2008) for 1000 steps and setting the perplexity parameter to 50.
Expression patterns of selected genes across cell clusters are shown in dot plots, which depict the fraction of cells in a cluster (row) that express a particular gene (column) based on the size of the dot, and the average number of transcripts in the expressing cells indicated by the color scale. We plotted the expression of selected cell surface, cytokines and transcription factor markers.
Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005) was run for each cell subset in pre-ranked list mode with 1,000 permutations (nominal P value cutoff < 0.01). Enrichment scores were visualized using the SeqGSEA package in R (Wang and Cairns, 2014) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Values are expressed as mean ± standard error of the mean (SEM) or standard deviation (SD) as indicated. Statistical analyses were performed by Linear Regression test, Mann-Whitney test or One-way ANOVA test followed by Tukey's multiple comparison test, unless otherwise indicated. Differences were considered statistically significant at p < 0.05. Analyses were performed with Prism (GraphPad Prism version 7.0).
DATA AND SOFTWARE AVAILABILITY
The sequence data genereated in this study have been deposited in the Gene Expression Omnibus (GEO) with the accession code GSE122969. The software used for the analyses for each of the data platforms and integrated analyses are described and referenced in the individual Method Details subsections.
